1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

0:53Shoppers,somewearingmasks,visitinamarket,July14,2022inLosAngeles,duringtheCOVID-19pandemic.LosAn ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN




entertainment

author：knowledge    Page View：55325
Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

advertisement

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Study finds new variant for Parkinson’s in African populations
Next article： At least 13 dead in Texas as scorching temps continue